+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
T-Cell Therapy Market - Global Forecast 2026-2032- Product Image
T-Cell Therapy Market - Global Forecast 2026-2032- Product Image
Sale

T-Cell Therapy Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083701
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The T-Cell Therapy Market is projected to reach USD 10.59 Billion in 2026. It is expected to continue growing at a CAGR of 21.57%, reaching USD 34.34 Billion by 2032.

The T-cell therapy market is moving from experimental oncology toward a diversified adoptive cell therapy ecosystem spanning CAR T-cell therapy, TCR therapy, tumor-infiltrating lymphocyte therapy, and emerging allogeneic platforms. Since the first FDA approvals of CAR T therapies in 2017, regulatory acceptance has expanded across hematologic malignancies, multiple myeloma, melanoma, and synovial sarcoma, supported by growing clinical evidence in relapsed or refractory disease settings.

For biopharma innovators, the strategic priority is no longer proof of concept alone. Competitive advantage now depends on durable clinical outcomes, scalable cell therapy manufacturing, payer-aligned real-world evidence, reliable logistics, and global regulatory execution across complex advanced therapy frameworks.

Transformative Shifts in the T-Cell Therapy Landscape

The landscape is shifting from single-product launches to platform-based development. Autologous CAR T remains clinically validated, while allogeneic T-cell therapy, in vivo engineering, gene-editing, armored T-cell constructs, and dual-target approaches are designed to address manufacturing time, relapse, antigen escape, and access limitations.

Solid tumors are becoming the next frontier. The 2024 FDA approvals of lifileucel for unresectable or metastatic melanoma and afamitresgene autoleucel for synovial sarcoma reinforced that T-cell therapy is extending beyond blood cancers, although tumor microenvironment resistance, antigen heterogeneity, biomarker selection, and patient identification remain decisive hurdles.

Cumulative Impact of Artificial Intelligence in T-Cell Therapy

Artificial intelligence is increasingly embedded across target discovery, antigen validation, construct design, clinical trial matching, patient stratification, and manufacturing quality control. AI-enabled analytics can help identify tumor antigens, predict T-cell fitness, detect process deviations, analyze high-dimensional immune profiling data, and support release testing for complex living medicines.

The cumulative impact is operational as much as scientific. Sponsors that integrate AI with validated datasets, compliant automation, explainable models, and electronic batch records can shorten development cycles while improving consistency, but regulated deployment requires strong data governance, cybersecurity controls, auditability, and human oversight.

Key Regional Insights Across Global T-Cell Therapy

North America remains the leading commercialization hub for T-cell therapy, supported by FDA experience with advanced biologics, major academic cancer centers, specialized apheresis and infusion networks, and established reimbursement pathways for approved CAR T-cell therapies. Europe is advancing through EMA centralized approvals, national health technology assessment processes, hospital exemption experience, and strong cell and gene therapy research clusters across Germany, France, Italy, Spain, and the United Kingdom.

Asia-Pacific is accelerating through China, Japan, South Korea, India, Australia, and ASEAN markets, combining large patient populations with expanding clinical trial capacity, supportive regenerative medicine frameworks, and increasing domestic manufacturing capabilities. Latin America is earlier in adoption, with Brazil and Mexico strengthening oncology referral systems and advanced therapy policy discussions. The Middle East, particularly high-income Gulf health systems, is investing in precision medicine, specialty hospitals, and international oncology partnerships, while Africa remains at an earlier access stage but is gradually building cancer care infrastructure, diagnostic capacity, and referral networks that can support future T-cell therapy readiness.

Key Group Insights for Strategic T-Cell Therapy Expansion

The G7 anchors premium innovation in T-cell therapy through advanced regulatory systems, oncology reimbursement experience, mature clinical trial infrastructure, and deep biomedical research capacity. The European Union provides harmonized marketing authorization through the EMA while leaving pricing and access decisions to member states, creating both scale and reimbursement complexity for CAR T-cell therapy, TCR therapy, and other advanced therapy medicinal products.

BRICS markets are increasingly important for clinical development, patient recruitment, and localized manufacturing, especially China and India, where oncology burden, cost-conscious innovation, and domestic biomanufacturing policies are shaping future access models. ASEAN is building medical tourism, oncology capacity, and regional clinical research networks; the GCC is investing in advanced hospitals, precision medicine programs, and cross-border specialty care; and NATO-aligned countries benefit from research collaboration, biomedical supply chain resilience, and shared clinical standards that can support advanced cell therapy deployment.

Key Country Insights for T-Cell Therapy Adoption

The United States leads commercial adoption with multiple FDA-approved CAR T-cell therapies, expanding use in earlier treatment lines, and a dense network of certified treatment centers. Canada benefits from strong academic centers and public health system experience but faces provincial reimbursement variation, while Mexico and Brazil represent long-term access opportunities as hematology-oncology infrastructure, referral pathways, and advanced therapy policy frameworks continue to mature.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine regulatory maturity, specialist cancer centers, and active health technology assessment processes that influence patient access timelines and evidence expectations. Russia faces access, investment, and geopolitical constraints. China has become a major CAR T development and clinical research hub; India is advancing cost-conscious innovation and domestic cell therapy capabilities; Japan and South Korea support advanced regenerative medicine regulation and hospital-based innovation; and Australia remains a strong clinical trial destination with established oncology research networks and high-quality regulatory oversight.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indication sequencing, differentiated antigen strategy, biomarker-enabled patient selection, and evidence generation that demonstrates durability, safety, quality of life improvement, and total cost-of-care value. Early payer and provider engagement is essential because T-cell therapies carry high upfront costs and require specialized leukapheresis, lymphodepletion, inpatient or outpatient monitoring, and toxicity management capabilities.

Manufacturers should invest in closed-system automation, decentralized or regionalized manufacturing models, cold-chain resilience, chain-of-identity controls, and digital vein-to-vein tracking. Partnerships with academic centers, contract development and manufacturing organizations, diagnostic developers, health systems, and AI specialists can reduce execution risk, accelerate site readiness, and improve consistency across clinical and commercial deployment.

Research Methodology

This executive summary is developed using secondary research from regulatory agencies, clinical trial registries, peer-reviewed literature, oncology guidelines, public health technology assessment sources, and publicly available industry disclosures. The analysis emphasizes verified market signals such as product approvals, clinical development trends, reimbursement dynamics, treatment center requirements, safety monitoring practices, and manufacturing constraints.

The methodology applies cross-validation across multiple credible sources to identify consistent patterns and reduce bias. Insights are structured around technology evolution, regional readiness, stakeholder economics, regulatory pathways, manufacturing feasibility, and commercialization requirements within the global T-cell therapy market, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

T-cell therapy has become one of the most important segments of precision oncology, with CAR T-cell therapy providing the commercial foundation and TCR therapy, TIL therapy, allogeneic platforms, and gene-edited approaches expanding the opportunity set. The field is supported by strong translational science, regulatory precedent, improving manufacturing methods, and urgent unmet need in relapsed, refractory, and difficult-to-treat cancers.

The next phase will reward organizations that combine clinical differentiation with manufacturing excellence, AI-enabled decision-making, robust real-world evidence, and equitable access strategies. Sustainable progress will depend on proving long-term value for patients, providers, payers, regulators, and health systems while improving reliability, affordability, and global availability.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. T-Cell Therapy Market, by Indication
7.1. Introduction
7.2. Autoimmune Diseases
7.2.1. Multiple Sclerosis
7.2.2. Psoriasis
7.2.3. Rheumatoid Arthritis
7.3. Infectious Diseases
7.3.1. Hepatitis B
7.3.2. Hepatitis C
7.3.3. HIV
7.4. Oncology
7.4.1. Leukemia
7.4.2. Lymphoma
7.4.3. Multiple Myeloma
7.4.4. Solid Tumors
7.4.4.1. Breast Cancer
7.4.4.2. Lung Cancer
7.4.4.3. Melanoma
8. T-Cell Therapy Market, by Therapy Type
8.1. Introduction
8.2. CAR T Cell Therapy
8.3. TCR T Cell Therapy
8.4. TIL Therapy
9. T-Cell Therapy Market, by Manufacturing Model
9.1. Introduction
9.2. Contract Manufacturing
9.3. In-House Manufacturing
10. T-Cell Therapy Market, by Cell Source
10.1. Introduction
10.2. Allogeneic
10.3. Autologous
11. T-Cell Therapy Market, by End User
11.1. Introduction
11.2. Hospital
11.3. Research Institute
11.4. Specialty Clinic
12. T-Cell Therapy Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. T-Cell Therapy Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. T-Cell Therapy Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Adaptimmune Therapeutics plc
16.2. Allogene Therapeutics Inc
16.3. ArsenalBio Inc
16.4. Atara Biotherapeutics Inc
16.5. Autolus Therapeutics plc
16.6. BioNTech SE
16.7. Brainchild Bio Inc
16.8. Bristol Myers Squibb Company
16.9. Cabaletta Bio Inc
16.10. Caribou Biosciences Inc
16.11. Cartesian Therapeutics Inc
16.12. Cellectis SA
16.13. Celyad Oncology SA
16.14. Eureka Therapeutics Inc
16.15. Fate Therapeutics Inc
16.16. Gilead Sciences Inc
16.17. Immatics NV
16.18. Iovance Biotherapeutics Inc
16.19. JW Therapeutics Co Ltd
16.20. Kite Pharma Incorporated
16.21. Kyverna Therapeutics Inc
16.22. Legend Biotech Corporation
16.23. Lyell Immunopharma Inc
16.24. Mustang Bio Inc
16.25. Novartis AG
16.26. Wugen Inc
List of Figures
FIGURE 1. GLOBAL T-CELL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL T-CELL THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL T-CELL THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL T-CELL THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2032 (%)
FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HEPATITIS C MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HEPATITIS C MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HEPATITIS C MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CAR T CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TCR T CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TCR T CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TCR T CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TIL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TIL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TIL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SPECIALTY CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. EUROPE T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 99. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 100. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 101. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 102. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 103. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 104. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 105. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 106. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. AFRICA T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 129. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 130. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 131. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 132. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 133. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 134. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 135. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 136. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. NATO T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. NATO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 150. NATO T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 151. NATO T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 152. NATO T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 153. NATO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 154. NATO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 155. NATO T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 156. NATO T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 157. NATO T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. G7 T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. G7 T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 160. G7 T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 161. G7 T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 162. G7 T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 163. G7 T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 164. G7 T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 165. G7 T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 166. G7 T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 167. G7 T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. BRICS T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. BRICS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 170. BRICS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 171. BRICS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 172. BRICS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 173. BRICS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 174. BRICS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 175. BRICS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 176. BRICS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 177. BRICS T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. ASEAN T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. ASEAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 190. ASEAN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 191. ASEAN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 192. ASEAN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 193. ASEAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 194. ASEAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 195. ASEAN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 196. ASEAN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 197. ASEAN T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. GCC T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. GCC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 200. GCC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 201. GCC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 202. GCC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 203. GCC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 204. GCC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 205. GCC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 206. GCC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 207. GCC T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 209. CHINA T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 211. CHINA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 212. CHINA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 213. CHINA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 214. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 215. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 216. CHINA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 217. CHINA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 218. CHINA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. JAPAN T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 231. JAPAN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 232. JAPAN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 233. JAPAN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 234. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 235. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 236. JAPAN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 237. JAPAN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 238. JAPAN T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. INDIA T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 241. INDIA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 242. INDIA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 243. INDIA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 244. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 245. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 246. INDIA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 247. INDIA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 248. INDIA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. GERMANY T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 251. GERMANY T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 252. GERMANY T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 253. GERMANY T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 254. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 255. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 256. GERMANY T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 257. GERMANY T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 258. GERMANY T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 267. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 268. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. AUSTRALIA T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 271. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 272. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 273. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 274. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 275. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 276. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 278. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. FRANCE T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 281. FRANCE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 282. FRANCE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 283. FRANCE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 284. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 285. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 286. FRANCE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 287. FRANCE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 288. FRANCE T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 293. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 294. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 295. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 296. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 297. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 298. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. ITALY T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 301. ITALY T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 302. ITALY T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 303. ITALY T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 304. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 305. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 306. ITALY T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 307. ITALY T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 308. ITALY T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. CANADA T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 311. CANADA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 312. CANADA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 313. CANADA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 314. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 315. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 316. CANADA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 317. CANADA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 318. CANADA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 321. RUSSIA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 322. RUSSIA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 323. RUSSIA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 324. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 325. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 326. RUSSIA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 327. RUSSIA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 328. RUSSIA T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. BRAZIL T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 330. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 331. BRAZIL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 332. BRAZIL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 333. BRAZIL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 334. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 335. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 336. BRAZIL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 337. BRAZIL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 338. BRAZIL T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. MEXICO T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 341. MEXICO T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 342. MEXICO T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 343. MEXICO T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 344. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 345. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 346. MEXICO T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 347. MEXICO T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 348. MEXICO T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 349. SPAIN T-CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 350. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 351. SPAIN T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2017-2032 (USD MILLION)
TABLE 352. SPAIN T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 353. SPAIN T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 354. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 355. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 356. SPAIN T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2017-2032 (USD MILLION)
TABLE 357. SPAIN T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2017-2032 (USD MILLION)
TABLE 358. SPAIN T-CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 359. GLOBAL T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 360. GLOBAL T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Adaptimmune Therapeutics plc
  • Allogene Therapeutics Inc
  • ArsenalBio Inc
  • Atara Biotherapeutics Inc
  • Autolus Therapeutics plc
  • BioNTech SE
  • Brainchild Bio Inc
  • Bristol Myers Squibb Company
  • Cabaletta Bio Inc
  • Caribou Biosciences Inc
  • Cartesian Therapeutics Inc
  • Cellectis SA
  • Celyad Oncology SA
  • Eureka Therapeutics Inc
  • Fate Therapeutics Inc
  • Gilead Sciences Inc
  • Immatics NV
  • Iovance Biotherapeutics Inc
  • JW Therapeutics Co Ltd
  • Kite Pharma Incorporated
  • Kyverna Therapeutics Inc
  • Legend Biotech Corporation
  • Lyell Immunopharma Inc
  • Mustang Bio Inc
  • Novartis AG
  • Wugen Inc

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.59 Billion
Forecasted Market Value ( USD ) by 2032 $ 34.34 Billion
Compound Annual Growth Rate21.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

T-Cell Immunotherapy Market - Global Forecast 2026-2032 - Product Image

T-Cell Immunotherapy Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Allogeneic Cell Therapy Market - Global Forecast 2026-2032 - Product Image

Allogeneic Cell Therapy Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Allogeneic T Cell Therapies Market Report 2026 - Product Image

Allogeneic T Cell Therapies Market Report 2026

  • Report
  • 250 Pages
  • Global
From
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - Product Image

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035: Distribution by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

  • Report
  • 598 Pages
  • Global
From
Cell Therapy Clinical Trial Services - Global Strategic Business Report - Product Image

Cell Therapy Clinical Trial Services - Global Strategic Business Report

  • Report
  • 487 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.